Real-world clinical outcomes and healthcare costs in patients with Crohn’s disease treated with vedolizumab versus ustekinumab in the United States

References

• The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5:17–30.
   PubMed Web of Science ®Google Scholar
• Crohn’s & Colitis Foundation of America [Internet]. The facts about inflammatory bowel diseases. 2014 [cited Sep 29, 2022]. https://www.crohnscolitisfoundation.org/sites/default/files/legacy/assets/pdfs/updatedibdfactbook.pdf.
   Google Scholar
• Loftus EV Jr. Update on the incidence and prevalence of inflammatory bowel disease in the United States. Gastroenterol Hepatol. 2016;12(11):704–707.
   Google Scholar
• Shivashankar R, Tremaine WJ, Harmsen WS, et al. Incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted county, Minnesota from 1970 through 2010. Clin Gastroenterol Hepatol. 2017;15(6):857–863. doi: 10.1016/j.cgh.2016.10.039.
   PubMed Web of Science ®Google Scholar
• Ye Y, Manne S, Treem WR, et al. Prevalence of inflammatory bowel disease in pediatric and adult populations: recent estimates from large national databases in the United States, 2007-2016. Inflamm Bowel Dis. 2020;26:619–625.
   PubMed Web of Science ®Google Scholar
• Gajendran M, Loganathan P, Catinella AP, et al. A comprehensive review and update on Crohn’s disease. Dis Mon. 2018;64(2):20–57. doi: 10.1016/j.disamonth.2017.07.001.
   PubMed Web of Science ®Google Scholar
• Manceur AM, Ding Z, Muser E, et al. Burden of Crohn’s disease in the United States: long-term healthcare and work-loss related costs. J Med Econ. 2020;23(10):1092–1101. doi: 10.1080/13696998.2020.1789649.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Shahabi A, Seabury SA, et al. Lifetime economic burden of Crohn’s disease and ulcerative colitis by age at diagnosis. Clin Gastroenterol Hepatol. 2020;18(4):889–897.e10. doi: 10.1016/j.cgh.2019.07.022.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113(4):481–517. doi: 10.1038/ajg.2018.27.
   PubMed Web of Science ®Google Scholar
• Skyrizi. Prescribing information. AbbVie Inc; 2022. https://www.rxabbvie.com/pdf/skyrizi_pi.pdf.
   Google Scholar
• Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2020;14(1):4–22. doi: 10.1093/ecco-jcc/jjz180.
   PubMed Web of Science ®Google Scholar
• Kawalec P, Moćko P. An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn’s disease patients. J Comp Eff Res. 2018;7(2):101–111. doi: 10.2217/cer-2017-0041.
   PubMed Web of Science ®Google Scholar
• Alric H, Amiot A, Kirchgesner J, et al. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn’s disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther. 2020;51(10):948–957. doi: 10.1111/apt.15706.
   PubMed Web of Science ®Google Scholar
• Biemans VBC, van der Woude CJ, Dijkstra G, et al. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti-TNF treatment. Aliment Pharmacol Ther. 2020;52(1):123–134. doi: 10.1111/apt.15745.
   PubMed Web of Science ®Google Scholar
• Manlay L, Boschetti G, Pereira B, et al. Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn’s disease refractory to anti-tumour necrosis factor therapy. Aliment Pharmacol Ther. 2021;53(12):1289–1299. doi: 10.1111/apt.16377.
   PubMed Web of Science ®Google Scholar
• Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol. 2011;106(4):674–684. doi: 10.1038/ajg.2011.60.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104(3):760–767. doi: 10.1038/ajg.2008.88.
   PubMed Web of Science ®Google Scholar
• Patel H, Lissoos T, Rubin DT. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn’s disease in the United States. PLOS One. 2017;12(4):e0175099. doi: 10.1371/journal.pone.0175099.
   PubMed Web of Science ®Google Scholar
• Park KT, Ehrlich OG, Allen JI, et al. The cost of inflammatory bowel disease: an initiative from the Crohn’s & colitis foundation. Inflamm Bowel Dis. 2020;26(1):1–10. doi: 10.1093/ibd/izz104.
   PubMed Web of Science ®Google Scholar
• Entyvio. Prescribing information. Takeda Pharmaceuticals U.S.A., Inc; 2022. https://www.general.takedapharm.com/ENTYVIOPI.
   Google Scholar
• Stelara. Prescribing information. Janssen Biotech Inc; 2019. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf.
   Google Scholar
• Hainmueller J. Entropy balancing for causal effects: a multivariate reweighting method to produce balanced samples in observational studies. Polit Anal. 2012;20(1):25–46. doi: 10.1093/pan/mpr025.
   Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
   Google Scholar
• Demuth D, Patel H, Chastek B, et al. Real-world treatment persistence with vedolizumab in Crohn’s disease and ulcerative colitis patients in the United States (US): a retrospective analysis using the Optum research database: 721. Am J Gastroenterol. 2016;111: s 324. doi: 10.14309/00000434-201610001-00721.
   Web of Science ®Google Scholar
• Obando C, Ding Z, Muser E, et al. Persistence, dose titration, and health care resource utilization among Crohn’s disease patients treated with ustekinumab: a real-world analysis in the United States. Adv Ther. 2020;37(5):2127–2143. doi: 10.1007/s12325-020-01276-3.
   PubMed Web of Science ®Google Scholar
• Teeple A, Sah J, Mallampati R, et al. Persistence, dosing, and other treatment patterns among Crohn’s disease patients initiating biologics in United States. Crohn’s Colitis. 2021;3:otab076.
   Google Scholar
• Dulai PS, Singh S, Jiang X, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: results from the US VICTORY consortium. Am J Gastroenterol. 2016;111(8):1147–1155. doi: 10.1038/ajg.2016.236.
   PubMed Web of Science ®Google Scholar
• Singh S. Network meta-analysis to inform positioning of biologics in patients with Crohn’s disease: promise and perils. Best Pract Res Clin Gastroenterol. 2019;38-39:101614. doi: 10.1016/j.bpg.2019.05.001.
   PubMed Web of Science ®Google Scholar